Myco Industries, Inc. Announces U.S. Patent and Trademark Office has issued U.S. Patent No. 10,404203 for the AB Maxtm
MILFORD, Mich., Sept. 19, 2019 /PRNewswire/ -- Myco Industries, Inc. (Myco), a privately held medical device company, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 10,404203 on September 3, 2019 for the AB Maxtm - a new advanced doctor's treatment for Anterior Blepharitis*.
John Choate, Chairman of Myco designed the AB Maxtm to provide medical professionals with advanced functionality utilizing two onboard computers and proprietary tips specifically designed to treat Anterior Blepharitis*. As the U.S. Patent Office recognized, AB Maxtm is a unique advancement over our competitor's device since Myco's patent covers the revolutionary pulse-mode feature of the AB Maxtm after reviewing our competitors' patent.
The AB Maxtm offers the same forward and reverse functionality as our competitor, but also has a patented PULSE mode specifically engineered to remove even the most tenacious scurf and debris, while massaging the outer eyelid margins for better patient outcomes.
Myco Industries, Inc. has been designing and manufacturing ophthalmic/optometric devices since 1993. Our mission is to help health care professionals provide the best possible care with the best possible outcomes through innovation. *Anterior Blepharitis is blepharitis of the outer eyelid margin, including the eyelashes. Patented and Patents Pending Myco Industries, Inc. For use by medical professionals only.
ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of microRNAs, today announced an oral presentation at the upcoming Oligonucleotide & Peptide Therapeutics (TIDES) Conference...
With every successive year, the lines between medical devices and consumer electronics become increasingly blurred ? medtech companies seek to expand their reach beyond patients, and consumer electronics companies have targeted medical applications...
The 31st Canadian Cancer Society (CCS) Daffodil Ball, which took place this evening at Windsor Station in Montreal, raised $1,474,785 to fund innovative research projects and essential support programs for people living with cancer. The largest...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....